Sanofi Total Assets 2010-2023 | SNY

Sanofi total assets from 2010 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Sanofi total assets for the quarter ending September 30, 2023 were $0.000B, a NAN% increase year-over-year.
  • Sanofi total assets for 2022 were $133.514B, a 6.15% decline from 2021.
  • Sanofi total assets for 2021 were $142.258B, a 8.74% increase from 2020.
  • Sanofi total assets for 2020 were $130.827B, a 3.61% increase from 2019.
Sanofi Annual Total Assets
(Millions of US $)
2022 $133,514
2021 $142,258
2020 $130,827
2019 $126,264
2018 $131,573
2017 $112,833
2016 $115,830
2015 $113,617
2014 $129,463
2013 $127,603
2012 $129,133
2011 $139,510
2010 $113,222
2009 $111,636
Sanofi Quarterly Total Assets
(Millions of US $)
2023-09-30 $0
2023-06-30 $136,685
2023-03-31 $0
2022-12-31 $133,514
2022-09-30 $0
2022-06-30 $129,647
2022-03-31 $0
2021-09-30 $0
2021-03-31 $0
2020-09-30 $0
2020-03-31 $0
2019-09-30 $0
2019-03-31 $0
2018-03-31 $0
2017-12-31 $112,833
2017-09-30 $0
2017-06-30 $112,077
2017-03-31 $0
2016-12-31 $115,830
2016-09-30 $0
2016-06-30 $111,958
2016-03-31 $0
2015-09-30 $0
2015-06-30 $108,322
2014-06-30 $124,450
2013-06-30 $126,655
2012-06-30 $130,750
2012-03-31 $0
2011-12-31 $139,510
2011-09-30 $0
2011-06-30 $143,306
2011-03-31 $0
2010-12-31 $113,222
2010-09-30 $0
2010-06-30 $110,057
2010-03-31 $0
2009-12-31 $111,636
2009-09-30 $0
2009-06-30 $104,552
2009-03-31 $0
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $123.368B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.189B 121.76
Novo Nordisk (NVO) Denmark $553.986B 45.64
Johnson & Johnson (JNJ) United States $389.835B 15.52
Merck (MRK) United States $328.029B 86.30
AbbVie (ABBV) United States $314.591B 16.03
Novartis AG (NVS) Switzerland $220.226B 15.26
AstraZeneca (AZN) United Kingdom $204.098B 18.09
Pfizer (PFE) United States $156.744B 15.17
Innoviva (INVA) United States $0.992B 8.95